Overview

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Antibodies, Monoclonal
Doxorubicin
Durvalumab
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin